Interleukin-17: A promoter in colorectal cancer progression

97Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

It is widely accepted that chronic inflammation plays an active role in cancer. Inflammatory immunocytes and related cytokines in the tumor microenvironment are supposed to be a "double-edged sword" in colorectal cancer (CRC) initiation and progression. Interleukin-17 (IL-17), a pleiotropic proinflammatory cytokine, can promote cancer-elicited inflammation and prevent cancer cells from immune surveillance. Despite controversy, IL-17 is generally considered to be a promoter in CRC progression. In this review, we devote to summarize the current progress regarding the role of IL-17 in tumor initiation and progression, as well as the prognostic value in CRC. © 2013 Dang Wu et al.

Cite

CITATION STYLE

APA

Wu, D., Wu, P., Huang, Q., Liu, Y., Ye, J., & Huang, J. (2013). Interleukin-17: A promoter in colorectal cancer progression. Clinical and Developmental Immunology. https://doi.org/10.1155/2013/436307

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free